Lion Point Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Lion Point Capital’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,500	Closed	-$371K	–	35
2023 Q4	$399K	Sell	13,500 -13,500	-50%	-$409K	0.2%	22
2023 Q3	$853K	Hold	27,000	–	–	0.38%	16
2023 Q2	$698K	Sell	27,000 -70,000	-72%	-$1.86M	0.32%	21
2023 Q1	$2.33M	Hold	97,000	–	–	0.96%	15
2022 Q4	$2.07M	Buy	97,000 +17,000	+21%	+$336K	0.29%	24
2022 Q3	$1.72M	Buy	+80,000	New	+$1.93M	0.38%	31

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lion Point Capital's MIRM Position: Q1 2024 in Review

Lion Point Capital sold out of Mirum Pharmaceuticals (MIRM) in Q1 2024, closing a stake of 13,500 shares — an estimated $371K sold.

Lion Point Capital first reported a position in MIRM in Q3 2022 and held it in 6 quarters. The position peaked at $2.33M in Q1 2023. 171 funds tracked by Wall St. Rank hold MIRM as of Q1 2024.

Lion Point Capital reported no remaining Mirum Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Lion Point Capital sold 13,500 Mirum Pharmaceuticals shares in Q1 2024, an estimated $371K.
Lion Point Capital first reported a position in Mirum Pharmaceuticals in Q3 2022 and held it in 6 quarters.
Lion Point Capital's Mirum Pharmaceuticals position peaked at $2.33M in Q1 2023.
171 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2024.

Based on Lion Point Capital's 13F filing for Q1 2024, filed 15 May 2024.